EW insider transaction filings
Edwards Lifesciences Corp — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-11. Screen EW transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 619 @ $72.68 · Sale (S): 619 @ $92.03 · Option exercise (M): 619 (derivative) @ $0 | EDGAR |
| 2026-07-30 | 4 | Markowitz Wayne — CVP, JAPAC | Sale (S): 146.31 @ $86.03 | EDGAR |
| 2026-07-28 | 4 | Markowitz Wayne — CVP, JAPAC | Option exercise (M): 9,628 @ $74.02 · Sale (S): 9,628 @ $85.06 · Option exercise (M): 9,628 (derivative) @ $0 | EDGAR |
| 2026-07-27 | 4 | Zovighian Bernard J — CEO, Director | Gift (G): 319.65 @ $0 · Gift (G): 319.65 @ $0 · Sale (S): 2,920.55 @ $83.93 | EDGAR |
| 2026-07-13 | 4 | Bruls Annette — CVP, EMEACLA | Tax withholding (F): 109 @ $92.21 | EDGAR |
| 2026-07-10 | 4 | Mistras Theodora — CVP, Chief Financial Officer | Grant/award (A): 87,595 @ $0 · Grant/award (A): 12,325 @ $0 · Grant/award (A): 61,800 (derivative) @ $0 · Grant/award (A): 12,325 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 619 @ $72.68 · Sale (S): 619 @ $91.70 · Option exercise (M): 619 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Lippis Daniel J. — CVP, TAVR | Tax withholding (F): 377 @ $95.18 | EDGAR |
| 2026-06-30 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 619 @ $72.68 · Sale (S): 619 @ $91.40 · Option exercise (M): 619 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Zovighian Bernard J — CEO, Director | Sale (S): 523 @ $87.92 | EDGAR |
| 2026-05-29 | 4 | Dahl Andrew M. — SVP, Corporate Controller | Sale (S): 567.53 @ $86.08 | EDGAR |
| 2026-05-27 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Sale (S): 23,145 @ $86.42 | EDGAR |
| 2026-05-22 | 4 | Chopra Daveen — CVP, TMTT & Surgical | Sale (S): 1,500 @ $84.60 | EDGAR |
| 2026-05-18 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 620 @ $72.68 · Sale (S): 620 @ $81.14 · Option exercise (M): 620 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Sale (S): 9,968 @ $82.07 · Sale (S): 8,000 @ $81.82 | EDGAR |
| 2026-05-12 | 4 | Zovighian Bernard J — CEO, Director | Option exercise (M): 47,207 @ $0 · Tax withholding (F): 26,198 @ $79.96 · Gift (G): 26,640 @ $0 · Gift (G): 26,640 @ $0 · Sale (S): 845 @ $78.40 · Sale (S): 35,506 @ $77.92 · +1 more | EDGAR |
| 2026-05-12 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Option exercise (M): 13,457 @ $0 · Tax withholding (F): 7,469 @ $79.96 · Option exercise (M): 13,457 (derivative) @ $0 | EDGAR |
| 2026-05-12 | 4 | Chopra Daveen — CVP, TMTT & Surgical | Option exercise (M): 13,583 @ $0 · Tax withholding (F): 7,538 @ $79.96 · Option exercise (M): 13,583 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Ullem Scott B. — CVP, Chief Financial Officer | Option exercise (M): 19,830 @ $0 · Tax withholding (F): 11,004 @ $79.96 · Option exercise (M): 19,830 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Markowitz Wayne — CVP, JAPAC | Grant/award (A): 5,200 @ $0 · Tax withholding (F): 264 @ $83.20 · Tax withholding (F): 226 @ $82.76 · Sale (S): 593 @ $79.73 · Grant/award (A): 26,400 (derivative) @ $0 · Grant/award (A): 5,200 (derivative) @ $0 | EDGAR |
| 2026-05-11 | 4 | Zovighian Bernard J — CEO, Director | Grant/award (A): 43,800 @ $0 · Tax withholding (F): 4,153 @ $83.20 · Gift (G): 4,222 @ $0 · Tax withholding (F): 5,398 @ $82.76 · Gift (G): 5,489 @ $0 · Gift (G): 4,222 @ $0 · +3 more | EDGAR |
| 2026-05-11 | 4 | Lippis Daniel J. — CVP, TAVR | Tax withholding (F): 362 @ $79.96 | EDGAR |
| 2026-05-08 | 4 | VALERIANI NICHOLAS J — Director | Grant/award (A): 5,127 @ $0 | EDGAR |
| 2026-05-08 | 4 | Sequeira Ramona — Director | Grant/award (A): 3,251 @ $0 | EDGAR |
| 2026-05-08 | 4 | LORANGER STEVEN R — Director | Grant/award (A): 3,251 @ $0 · Grant/award (A): 1,064 @ $0 | EDGAR |
| 2026-05-08 | 4 | LAVIOLETTE PAUL A — Director | Grant/award (A): 3,251 @ $0 | EDGAR |
| 2026-05-08 | 4 | STONE HEISZ LESLIE — Director | Grant/award (A): 3,251 @ $0 | EDGAR |
| 2026-05-08 | 4 | GALLAHUE KIERAN — Director | Grant/award (A): 3,251 @ $0 · Grant/award (A): 1,064 @ $0 | EDGAR |
| 2026-05-08 | 4 | Feinberg David T — Director | Grant/award (A): 3,251 @ $0 | EDGAR |
| 2026-05-08 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Grant/award (A): 7,850 @ $0 · Tax withholding (F): 831 @ $83.20 · Tax withholding (F): 1,038 @ $82.76 · Grant/award (A): 44,000 (derivative) @ $0 · Grant/award (A): 7,850 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Ullem Scott B. — CVP, Chief Financial Officer | Tax withholding (F): 1,373 @ $83.20 · Tax withholding (F): 1,661 @ $82.76 | EDGAR |
| 2026-05-08 | 4 | Davis Leslie C. — Director | Grant/award (A): 3,251 @ $0 | EDGAR |
| 2026-05-08 | 4 | Lippis Daniel J. — CVP, TAVR | Grant/award (A): 7,850 @ $0 · Tax withholding (F): 309 @ $83.20 · Tax withholding (F): 450 @ $82.76 · Grant/award (A): 39,900 (derivative) @ $0 · Grant/award (A): 7,850 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Dahl Andrew M. — SVP, Corporate Controller | Grant/award (A): 3,985 @ $0 · Grant/award (A): 3,020 @ $0 · Tax withholding (F): 289 @ $82.76 · Grant/award (A): 6,745 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Chopra Daveen — CVP, TMTT & Surgical | Grant/award (A): 9,675 @ $0 · Tax withholding (F): 674 @ $83.20 · Tax withholding (F): 1,141 @ $82.76 · Grant/award (A): 49,100 (derivative) @ $0 · Grant/award (A): 9,675 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | Bruls Annette — CVP, EMEACLA | Grant/award (A): 6,650 @ $0 · Tax withholding (F): 84 @ $82.76 · Grant/award (A): 33,700 (derivative) @ $0 · Grant/award (A): 6,650 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Ullem Scott B. — CVP, Chief Financial Officer | Tax withholding (F): 620 @ $83.98 · Option exercise (M): 13,000 @ $59.26 · Tax withholding (F): 11,131 @ $82.91 · Option exercise (M): 13,000 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | Zovighian Bernard J — CEO, Director | Tax withholding (F): 515 @ $83.98 · Gift (G): 523 @ $0 · Gift (G): 523 @ $0 | EDGAR |
| 2026-05-04 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 1,019 @ $59.26 · Sale (S): 19 @ $83.99 · Sale (S): 1,000 @ $82.99 · Tax withholding (F): 252 @ $83.98 · Option exercise (M): 1,019 @ $59.26 · Sale (S): 1,019 @ $83.98 · +2 more | EDGAR |
| 2026-05-04 | 4 | Chopra Daveen — CVP, TMTT & Surgical | Tax withholding (F): 282 @ $83.98 | EDGAR |
| 2026-05-04 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Tax withholding (F): 469 @ $83.98 | EDGAR |
| 2026-04-09 | 4 | Ullem Scott B. — CVP, Chief Financial Officer | Option exercise (M): 13,000 @ $59.26 · Sale (S): 4,676 @ $80.50 · Sale (S): 8,324 @ $79.79 · Option exercise (M): 13,000 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 1,019 @ $59.26 · Sale (S): 1,019 @ $80.98 · Option exercise (M): 1,019 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Option exercise (M): 22,680 @ $59.26 · Sale (S): 4,676 @ $80.59 · Sale (S): 18,004 @ $80.05 · Option exercise (M): 22,680 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Ullem Scott B. — CVP, Chief Financial Officer | Option exercise (M): 13,000 @ $59.26 · Sale (S): 5,099 @ $84.46 · Sale (S): 7,901 @ $85.21 · Option exercise (M): 13,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Lippis Daniel J. — CVP, TAVR | Option exercise (M): 1,019 @ $59.26 · Sale (S): 1,019 @ $85.38 · Option exercise (M): 1,019 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Option exercise (M): 11,340 @ $59.26 · Sale (S): 11,340 @ $85.93 · Option exercise (M): 11,340 (derivative) @ $0 | EDGAR |
| 2026-02-26 | 4 | BOBO DONALD E JR — CVP,Strategy/Corp Development | Sale (S): 24,000 @ $83.84 | EDGAR |
| 2026-02-23 | 4 | Lippis Daniel J. — CVP, TAVR | Tax withholding (F): 432 @ $79.78 | EDGAR |
| 2026-02-23 | 4 | Dahl Andrew M. — SVP, Corporate Controller | Tax withholding (F): 176 @ $79.78 | EDGAR |
Recent 8-K events — Edwards Lifesciences Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-04-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-19 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-06 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EW returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →